Filtered By:
Drug: Rituxan
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 265 results found since Jan 2013.
Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology
DISCUSSION: The panel achieved broad consensus on issues related to how to treat children with newly diagnosed ITP, providing a comprehensive review of all relevant clinical aspects.PMID:37677093 | DOI:10.2450/BloodTransfus.501
Source: Blood Transfusion - September 7, 2023 Category: Hematology Authors: Giovanna Russo Emilia Parodi Piero Farruggia Lucia D Notarangelo Silverio Perrotta Maddalena Casale Simone Cesaro Giovanni Del Borrello Giovanni C Del Vecchio Fiorina Giona Chiara Gorio Saverio Ladogana Giuseppe Lassandro Antonio Marzollo Karolina Maslak Source Type: research
Humoral and T-cell response to SARS-CoV-2 vaccination in patients with rheumatoid arthritis
CONCLUSION: In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, two out of ten patients did not develop IgG anti-SARS-CoV-2, 70% presented neutralizing activity and 65% specific T-cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, while treatment with ABA and RTX resulted in an impaired IgG anti-SARS-CoV-2 formation and neutralizing activity. This article is protected by copyright. All rights reserved.PMID:37605835 | DOI:10.1002/acr.25221
Source: Cell Research - August 22, 2023 Category: Cytology Authors: Carolina A Isnardi Margarita Landi Leonel Cruces Pablo Maid Claudia Calle Montoro Mar ía A Alfaro Brian M Rold án Andrea B G ómez Vara Pamela Giorgis Roberto A Ezquer Mar ía G Crespo Rocha Camila R Reyes G ómez Mar ía Á Correa Osvaldo L Cerda Marco Source Type: research
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
Int Immunopharmacol. 2023 Jun 3;120:110342. doi: 10.1016/j.intimp.2023.110342. Online ahead of print.ABSTRACTWe conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in ...
Source: International Immunopharmacology - June 5, 2023 Category: Allergy & Immunology Authors: Xavier Boumaza Margaux Lafaurie Emmanuel Treiner Ondine Walter Gregory Pugnet Guillaume Martin-Blondel Damien Biotti Jonathan Ciron Arnaud Constantin Marie Tauber Florent Puisset Guillaume Moulis Laurent Alric Yves Renaudineau Dominique Chauveau Laurent S Source Type: research
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review
CONCLUSION: Both types of the mRNA-vaccines and the AstraZeneca COVID-19 vaccines are highly effective and safe in patients with ARD. However, due to their suboptimal response in some patients, alternative mitigation strategies such as booster vaccines and shielding practices should also be followed. Management of immunomodulatory treatment regimens during the peri vaccination period should be individualized through shared decision making with patients and their attending rheumatologists.PMID:37244811 | PMC:PMC10201317 | DOI:10.1016/j.vaccine.2023.05.048
Source: Vaccine - May 27, 2023 Category: Allergy & Immunology Authors: Anwar I Joudeh Abdu Qaid Lutf Salah Mahdi Gui Tran Source Type: research
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
CONCLUSION: Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.PMID:37214149 | PMC:PMC10193112 | DOI:10.7774/cevr.2023.12.2.107
Source: Cell Research - May 22, 2023 Category: Cytology Authors: Chayapa Thookhamme Manassamon Navinpipat Aimwipa Sasakul Pakthipa Pattarakosol Kamoltip Lertchaisataporn Kriangkrai Tawinprai Pannee Praditsuktavorn Source Type: research
